BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 23570584)

  • 1. Mature B-cell lymphoma and leukemia in children and adolescents-review of standard chemotherapy regimen and perspectives.
    Worch J; Rohde M; Burkhardt B
    Pediatr Hematol Oncol; 2013 Sep; 30(6):465-83. PubMed ID: 23570584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant non-Hodgkin's lymphoma of childhood and adolescence in Austria--therapy results between 1986 and 2000.
    Attarbaschi A; Mann G; Dworzak M; Trebo M; Urban C; Fink FM; Horcher E; Reiter A; Riehm H; Gadner H;
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):978-86. PubMed ID: 12635465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-Münster Group.
    Seidemann K; Tiemann M; Lauterbach I; Mann G; Simonitsch I; Stankewitz K; Schrappe M; Zimmermann M; Niemeyer C; Parwaresch R; Riehm H; Reiter A;
    J Clin Oncol; 2003 May; 21(9):1782-9. PubMed ID: 12721255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy of advanced-stage mature B-cell lymphoma and leukemia in children and adolescents with rituximab and reduced intensity induction chemotherapy (B-NHL 2004M protocol): the results of a multicenter study.
    Samochatova EV; Maschan AA; Shelikhova LN; Myakova NV; Belogurova MB; Khlebnikova OP; Shamardina AV; Ryskal OV; Roumiantseva JV; Konovalov DM; Dubrovina ME; Rumyantsev AG
    J Pediatr Hematol Oncol; 2014 Jul; 36(5):395-401. PubMed ID: 23823112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-Hodgkin's lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols.
    Burkhardt B; Oschlies I; Klapper W; Zimmermann M; Woessmann W; Meinhardt A; Landmann E; Attarbaschi A; Niggli F; Schrappe M; Reiter A
    Leukemia; 2011 Jan; 25(1):153-60. PubMed ID: 21030984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparing CHOP, CHOP+HD-MTX,and BFM-90 regimens in the survival rate of children and adolescents with B cell non-Hodgkin's lymphoma].
    Sun XF; Su YS; Liu DG; Jiang WQ; He YJ; Lin TY; Huang HQ; Zhang L; Xia ZJ; Li YH; Zhou ZM; Chen XQ; Xia Y; Zhen ZJ; Guan ZZ
    Ai Zheng; 2004 Aug; 23(8):933-8. PubMed ID: 15301718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Head and neck presentations of B-NHL and B-AL in children/adolescents: experience of the LMB89 study.
    Lervat C; Auperin A; Patte C; Méchinaud F; Leverger G; Nelken B; Bertrand Y; Baruchel A; Coze C; Munzer M; Lacombe MJ; Bergeron C
    Pediatr Blood Cancer; 2014 Mar; 61(3):473-8. PubMed ID: 23970385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: a population-based analysis of the Austrian Cooperative Study Group.
    Attarbaschi A; Dworzak M; Steiner M; Urban C; Fink FM; Reiter A; Gadner H; Mann G
    Pediatr Blood Cancer; 2005 Jan; 44(1):70-6. PubMed ID: 15368550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of the efficacy of CCCG-97 and BFM-90 protocols in the treatment for children with mature B-cell non-Hodgkin's lymphoma].
    Meng JH; Gao YJ; Lu FJ; Zhai XW; Wang HS; Li J
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):222-7. PubMed ID: 22780979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphoma in children and adolescents. Part 3: An intermediate term analysis of the B-NHL/B-ALL].
    Reiter A; Schrappe M; Yakisan E; Sauter S; Ebell W; Zimmermann M; Hartmann W; Kremens B; Kuhn N; Claviez A
    Klin Padiatr; 1994; 206(4):242-52. PubMed ID: 7967420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphomas in children and adolescents. Part 1: Classification and allocation to strategic therapy groups. BIF study group].
    Reiter A; Tiemann M; Ludwig WD; Wacker HH; Yakisan E; Schrappe M; Henzler D; Sykora KW; Brandt A; Odenwald E
    Klin Padiatr; 1994; 206(4):222-33. PubMed ID: 7967418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results of the first Italian Association of Pediatric Hematology and Oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92).
    Pillon M; Di Tullio MT; Garaventa A; Cesaro S; Putti MC; Favre C; Lippi A; Surico G; Di Cataldo A; D'Amore E; Zanesco L; Rosolen A
    Cancer; 2004 Jul; 101(2):385-94. PubMed ID: 15241838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
    Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL
    Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence.
    Burkhardt B; Zimmermann M; Oschlies I; Niggli F; Mann G; Parwaresch R; Riehm H; Schrappe M; Reiter A;
    Br J Haematol; 2005 Oct; 131(1):39-49. PubMed ID: 16173961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma.
    Nagai H; Yano T; Watanabe T; Uike N; Okamura S; Hanada S; Kawano F; Sunami K; Inoue N; Sawamura M; Nishiura T; Hotta T; Horibe K
    Br J Haematol; 2008 Dec; 143(5):672-80. PubMed ID: 18950459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
    Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
    Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD20 positive childhood B-non Hodgkin lymphoma (B-NHL): morphology, immunophenotype and a novel treatment approach: a single center experience.
    Bilić E; Femenić R; Konja J; Simat M; Dubravcić K; Batinić D; Ries S; Rajić L
    Coll Antropol; 2010 Mar; 34(1):171-5. PubMed ID: 20432747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials.
    Griffin MM; Morley N
    Expert Opin Biol Ther; 2013 May; 13(5):803-11. PubMed ID: 23560506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of administering pediatric treatment to adolescent patients with mature B-cell non-Hodgkin lymphoma within the Japanese Pediatric Leukemia/Lymphoma Study Group clinical trial.
    Sekimizu M; Hashimoto H; Mori T; Kobayashi R; Horibe K; Tsurusawa M
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27068. PubMed ID: 29637700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.